Skip to main content

Table 3 Lung deposition and regional airway depositiona by COPD severity (PP analysis set)

From: A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease

Variable

Moderate COPD

Severe/very severe COPD

Severe/very severe vs. moderate COPD

 

LSM (SE) (N = 9)

LSM (SE) (N = 8)

Difference in

LSM (SE)

95% CI

Emitted dose in lungs, %

35.8 (5.7)

30.1 (6.1)

− 5.8 (8.3)

− 24.1, 12.6

Emitted dose in oropharyngeal

 + stomach regions, %

63.6 (5.5)

69.0 (5.9)

5.3 (8.1)

− 12.5, 23.1

Emitted dose in exhalation filter, %

0.5 (0.3)

1.0 (0.3)

0.5 (0.5)

− 0.6, 1.5

Ex-valve dose on actuator, %

12.2 (0.6)

10.4 (0.6)

− 1.8 (0.8)

− 3.6, 0.04

Regional airway deposition ratio:

 O/I

0.95 (0.11)

1.08 (0.12)

0.13 (0.16)

− 0.23, 0.48

 C/P

0.99 (0.21)

0.86 (0.23)

− 0.13 (0.31)

− 0.82, 0.56

 PI

0.48 (0.05)

0.60 (0.06)

0.11 (0.08)

− 0.06, 0.28

 sC/P

2.49 (0.51)

1.96 (0.55)

− 0.53 (0.75)

− 2.18, 1.12

  1. aFollowing a breath-hold of up to 10 s after each inhalation
  2. COPD chronic obstructive pulmonary disease, CI confidence interval, C/P central to peripheral, LSM least squares mean, O/I outer to inner, PI penetration index, PP per protocol, sC/P standardized central/peripheral, SE standard error